Ra Capital Management, L.P. Astria Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $6.17 Billion
- Q4 2024
A detailed history of Ra Capital Management, L.P. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 5,105,213 shares of ATXS stock, worth $35.9 Million. This represents 0.73% of its overall portfolio holdings.
Number of Shares
5,105,213
Previous 5,105,213
-0.0%
Holding current value
$35.9 Million
Previous $56.2 Million
19.98%
% of portfolio
0.73%
Previous 0.78%
Shares
5 transactions
Others Institutions Holding ATXS
# of Institutions
115Shares Held
50.3MCall Options Held
75KPut Options Held
6.2K-
Perceptive Advisors LLC New York, NY6.49MShares$45.6 Million1.91% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$29.4 Million2.22% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$25 Million6.29% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$24.7 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.87MShares$20.2 Million4.34% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $107M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...